header logo image


Page 990«..1020..989990991992..1,0001,010..»

Blood sport blindness afflicts our politicians – Holyrood.com

June 8th, 2017 1:42 am

Fox - credit gingiber

Humanity and compassion have been on the forefront of peoples minds in recent weeks, and even demonstrated by our politicians.

What a shame, though, that there cant be more compassion shown towards the animal kingdom at a time when the enjoyment of inflicting pain and death on fellow creatures is as popular as ever.

And it even featured in the Conservative manifesto.

RELATED CONTENT

Nearly one in three satellite tagged golden eagles in Scotland died in suspicious circumstances, finds SNH

MSPs to consider banning wild animals from travelling circuses

Theresa May tells voters she is in favour of fox hunting

The UK Environment, Food and Rural Affairs Secretary, Andrea Leadsom, who self-identifies as an animal lover, recently tweeted: Fully committed to protecting rare species in our Conservative manifesto. Saving iconic and hugely loved elephant is vital.

This is a ludicrous assessment of a manifesto which dropped a commitment to a ban on the sale of ivory.

Its a mystifying move given that an elephant is killed by poachers every 25 minutes, as the march towards extinction gathers apace; and it is far, far too late for politicians to be worrying about their popularity among the crucial wealthy antique-dealer electorate.

Perhaps less surprising is the indication that restrictions on fox hunting will be repealed.

Leadsom has said preventing hunters in traditional dress driving a pack of dogs through the countryside to chase then rip apart a fox has not proven to be in the interests of animal welfare whatsoever.

And Theresa May told some factory workers she was in favour of hunting.

Trying to explain fox hunting to my seven-year-old daughter is a difficult process, because while children can be very cruel, they also understand cruelty should not be fun.

The hunting lobby argues that people who oppose it the majority of people fail to understand the longstanding traditions and pursuits of countryside life, that people who live in cities over-sentimentalise animals.

Even leaving aside the class element to that, these arguments fall flat because they are condescending and fickle. However you dress it up, cruelty is cruelty. A culture of cruelty. Even a seven-year-old can understand that.

Compassion is not ignorant. Finding blood sport abhorrent is not complicated, it is principled. Its human.

And blood sport blindness is not exclusively a Tory pastime. The Scottish Government is considering relaxing the ban on amputating puppies tails introduced in 2007.

New exemptions would apply to just two breeds and only if they are likely to be used as a working dog, but the British Veterinary Association told MSPs that any concession would be a retrograde step for Scotland when prior to now it has always been cited as a key example of the Scottish lead on animal welfare.

Arguments for introducing exemptions come from another community of enthusiastic blood sport fanatics. Evidence shows gun dogs who work, particularly Spaniels, are at risk of injury if they have a tail.

But instead of examining the bloodthirsty practice that causes such injuries to these dogs, the answer instead is to mutilate the animal when they are born, and without any pain relief. The fact a dog uses its tail for balance and communication is inconvenient in such a job, apparently.

If your dog is suffering life-threatening injuries during your pursuit of the murder of birds, just maybe that isnt the fault of its tail.

Add in the corpses of driven grouse and the death of a number of inconvenient birds of prey - one in three golden eagles - as well as an annual cull of meddlesome mountain hares, and countryside pursuits is racking up quite the body count.

Will animal rights legislation ever recognise the culpability of the human in the equation?

We are supposed to be special because we have reason and rational thought. Indeed, Scotland is famous for both. But theres really nothing reasonable or rational about cruelty.

Time for some humanity and compassion in the face of barbarism.

Read the rest here:
Blood sport blindness afflicts our politicians - Holyrood.com

Read More...

Puma Biotechnology’s Neratinib Set To Target Extended Adjuvant Opportunity – Seeking Alpha

June 8th, 2017 1:41 am

Puma Biotechnology (NYSE:PBYI) is inching closer to its transformation from a research and development (or R&D) biopharmaceutical company to a full-fledged commercial organization. This company which has in-licensed development and commercialization rights for oral and intravenous formulations of irreversible tyrosine kinase inhibitor or TKI, neratinib, and also another irreversible TKI, PB357, achieved the first major milestone for 2017 on May 24, 2017. On this day, FDA's Oncologic Drugs Advisory Committee or ODAC recommended approval for Nerlynx (neratinib) as extended adjuvant therapy for patients suffering with early stage, human epidermal growth factor receptor type 2 - positive or HER2-positive breast cancer after being previously treated with surgery and adjuvant treatment with Roche Holdings' (OTCQX:RHHBY) Herceptin (trastuzumab).

Besides this indication, Puma Biotechnology expects neratinib to demonstrate efficacy in other cancers such a non small cell lung cancer and tumors related to expression or over-mutation in HER2 such as HER2-positive cancer, HER-2 cancer that has metastasized to brain, HER2-positive neoadjuvant breast cancer.

Hence, there is high probability that Neratinib can prove to be a blockbuster drug for Puma Biotechnology. I believe this is a solid reason for considering the company as a favorable investment opportunity in 2017. In this article, I will explain the key drivers that make Puma Biotechnology a compelling investment opportunity in 2017.

Extended adjuvant setting is a larger underserved market segment

Currently, the target breast cancer market in extended adjuvant setting comprises around 36,000 patients in USA and 34,000 in EU. In 2015, Herceptin's sales in adjuvant indication were around $4.5 billion to $5.0 billion. All these patients form a target market for neratinib in the following year. Currently, letrozole is the only FDA approved therapy in extended adjuvant setting.

Puma Biotechnology expects to launch Neratinib as extended adjuvant breast cancer therapy in 2017

In July 2016, Puma Biotechnology filed new drug application or NDA with FDA, seeking approval for neratinib in extended adjuvant setting for early stage HER2-overexpressed/amplified breast cancer. The regulatory agency accepted the application in September 2016.

Further, the European Medicines Agency or EMA also validated Puma's application for neratinib in extended adjuvant setting in August 2016. On advice of EMA, in March 2017, the company revised its label to only include those early stage HER2+ breast cancer patients who had been previously treated for up to 1 year with adjuvant herceptin. Puma Biotechnology initiated a managed access program for neratinib in this indication in Q4 2016 and an expanded access program in Q1 2017.

While all these have been major milestones for the company in the past, the upcoming milestone will be FDA approval for orally administered neratinib in extended adjuvant setting, anticipated in 3Q 2017.

This approval is expected to be mainly based on results obtained from phase 3 trial, ExteNET, in which neratinib managed to hit its primary endpoints. In the intent-to-treat or ITT population, the 2-year disease free survival or DFS in neratinib arm was seen to be 93.9% while that in the placebo arm was 91.6%, which implies absolute improvement of 2.4%. In ITT population, there has been a 2.5% absolute improvement in 5-year DFS for neratinib arm as compared to placebo arm.

In case of patients confirmed with HER+ breast cancer, neratinib demonstrated 2-year DFS of 94.7%, while it was only 90.6% for the placebo arm. While this is an absolute improvement of 4.1%, the 5-year DFS with neratinib in HER+ patients is slightly higher at 4.4%.

Data from ExteNET trial has also shown 33% reduction in risk of disease recurrence for patients in neratinib arm as compared to those in placebo arm in ITT population. Further, for confirmed HER+ early stage breast cancer patients, the reduction in risk of disease recurrence for those on neratinib therapy in extended adjuvant setting is as high as 49%.

All these statistics are in line with those seen for the already approved extended adjuvant breast cancer drug, letrozole, as well as data obtained from development trials for hormone receptor positive or HR+ adjuvant breast cancer therapies, Pfizer's (NYSE:PFE) Aromasin and AstraZeneca's (NYSE:AZN) Arimidex. This implies that there are high chances for neratinib to secure FDA approval in extended adjuvant setting.

Neratinib has demonstrated higher benefit as adjuvant therapy in HR+ breast cancer patients

For HR+ breast cancer patients in ExteNET trial, the adjuvant therapy of neratinib demonstrated DFS rate of 95.4%, while the placebo arm showed DFS of 91.2%. This implied an absolute benefit of 4.2% after 2 years.

For 5-year period, the DFS with neratinib in HR+ patients was 91.7% while that in placebo arm was 86.9%, implying 4.8% absolute benefit.

Neratinib has demonstrated superior results in HR+ patients mainly on account of dual suppression of the crosstalk between estrogen receptor-positive or ER+ and HER+. Since ER+ breast cancer patients in the ExteNET trial were already on background endocrine therapy, it helped suppress the ER while neratinib suppressed both EGFR and HER2. This dual suppression has been seen only in neratinib and not in trials of other breast cancer drugs such Roche Holdings Herceptin and Novartis' (NYSE:NVS) Tykerb.

In case of HR- patients, however, ExteNET trial demonstrated improvement with neratinib between months 0 to 12 as compared to placebo. This was essentially when the patients were being administered the drug. However, the benefit in DFS in the neratinib arm over placebo arm seemed to become statistically insignificant over 5 year horizon.

Puma Biotechnology has also introduced loperamide prophylaxis therapy to prevent diarrhea resulting from neratinib.

Prior to Puma Biotechnology in-licensing Neratinib, it was being tested on 3,000 patients in various trials. It was seen that these patients suffered from grade 3 or grade 4 diarrhea in the first 28 days after initiating therapy. However, this could be treated with antidiarrheal drug, loperamide.

Puma Biotechnology is instead focusing on preventing this side-effect of neratinib using loperamide prophylaxis. Data from multiple studies has shown that the rate of grade 3 diarrhea reduced from the range of 30% to 53% in case of no loperamide prophylaxis to the range of 0% to 17% with loperamide prophylaxis. The total duration of diarrhea also dropped from 14 days to 2 days with loperamide prophylaxis.

Since ExteNET trial did not involve any anti-diarrheal prophylaxis therapy, Puma Biotechnology separately studied the impact of loperamide prophylaxis alone and in combination with other anti-inflammatory agents in extended adjuvant setting in early stage HER2+ breast cancer patients in another phase 2 trial, CONTROL. Data from this trial showed that while rate of grade 3 diarrhea in ExteNET trial was 39.8%, loperamide prophylaxis reduced the rate to 30.7%, loperamide and budesonide prophylaxis to 23.4%, and loperamide and colestipol to 11.5%.

Further, while the duration of diarrhea in ExteNET trial was 59 days, the various prophylaxis regimens in the CONTROL trial have brought the down to the range of 8 to 12 days. Episodes of diarrhea were also brought down from 8 in ExteNET trial to the range of 2 to 4 in CONTROL trial.

The CONTROL trial has also shown improvement in tolerability for the drug, which was being mainly affected due to diarrhea.

All this shows that the major side-effect of Neratinib, diarrhea, is easily manageable with effective prophylaxis therapy. Further, it is only seen that grade 3 diarrhea was witnessed by patients only in first cycle or first 28 days of neratinib therapy.

The company's cash reserves can sustain its operations through mid-2018

At the end of Q1 2017, Puma Biotechnology had $194 million worth cash reserves on its balance sheet. The company's cash burn rate in Q1 2017 was $36.0 million. This can be considered representative for all the quarters in 2017, as Puma has been highly involved in preparing for regulatory approval and commercial launch of neratinib. Based on these assumptions, the company can sustain its business operations upto the first half of 2018, without depending on external funding.

Further, with a solid oncology drug in the pipeline, Puma Biotechnology will also not find it difficult to raise capital from the public, either as equity or debt. Hence, the company seems to be at a comfortable position.

Investors should not ignore certain company-specific risks

Today, Puma Biotechnology is equivalent to neratinib. In absence of any commercial product or advanced stage research product, Puma Biotechnology is excessively dependent on the successful commercial launch of Neratinib. Since the product has not yet received FDA approval for even a single indication, this may prove to be too risky investment for investors with average risk appetite.

Further, the company also does not have proven marketing and distribution capabilities. In absence of a strong commercial partner, Puma Biotechnology may land up being commercially unsuccessful, despite securing FDA approval for neratinib.

Investors should consider these major risk factors while considering Puma Biotechnology as an opportunity in 2017.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

Read the original:
Puma Biotechnology's Neratinib Set To Target Extended Adjuvant Opportunity - Seeking Alpha

Read More...

WSJ’s Grant: In biotech, no news is bad news – Seeking Alpha

June 8th, 2017 1:41 am

The American Society of Clinical Oncology annual meeting passed without much of a stir, writes Charley Grant in the WSJ. Naturally, there were exceptions with individual companies, but the biotech sector as a whole barely budged throughout the major conference.

So what? The S&P Biotechnology Select Industry Index isup 19%in 2017, and there are treatment categories outside of oncology. But, says Grant, the majority of stocks in that index aren't profitable, and are thus dependent on things like ASCO to rev up sentiment. In the bull market of 2013-15, ASCO was enough to send the sector sharply higher.

With that catalyst not working this year, all biotech may have to look forward to are blockbuster drug launches, and there's not much going on there - just three drugs are set to come to market this year that are expected to top $2B in annual sales by 2022.

ETFs: IBB, XBI, LABU, BBH, FBT, HQL, PBE, LABD, BBC, BBP, UBIO, ZBIO, LABS

Read more:
WSJ's Grant: In biotech, no news is bad news - Seeking Alpha

Read More...

AbbVie’s rheumatoid arthritis drug succeeds in trial – Reuters

June 8th, 2017 1:41 am

AbbVie Inc said on Wednesday its oral rheumatoid arthritis drug succeeded in a late-stage study on patients who had not adequately responded to standard treatments.

The drug, upadacitinib, is a once-daily pill belonging to a class of drugs known as JAK inhibitors, which block inflammation-causing enzymes called Janus kinases.

Pfizer Inc's Xeljanz is the only U.S.-approved JAK inhibitor for rheumatoid arthritis a chronic inflammatory disease in which the immune system attacks tissues in the joints, affecting more than 23 million people.

AbbVie's success comes almost two months after the U.S. Food and Drug Administration rejected baricitinib, a rival JAK inhibitor developed by Eli Lilly and Co and Incyte Corp.

If approved, upadacitinib could help AbbVie lower its reliance on its flagship rheumatoid arthritis drug Humira the world's top selling medicine that will soon face competition from biosimilars in the United States.

AbbVie's shares were up 1.4 percent at $68.81 on Wednesday afternoon. They earlier hit a session high of $69.32, their highest since August 2015.

In AbbVie's 12-week study on upadacitinib, two doses of the drug were tested against a placebo on patients with moderate-to-severe rheumatoid arthritis.

AbbVie said 64 percent of patients given a 15-milligram dose and 66 percent of patients given a 30-mg dose experienced a 20 percent reduction in symptoms, measured using a commonly used rheumatoid arthritis scale.

The company said only 36 percent of patients given a placebo experienced a comparable drop in symptoms, meaning upadacitinib cleared the trial the first of six testing the drug on patients with various cases of rheumatoid arthritis.

As data from the other trials comes in, upadacitinib might prove to be more effective than Lilly and Incyte's baricitinib, Jefferies analyst Jeffrey Holford said.

Rheumatoid arthritis is currently treated with older drugs such as methotrexate, Pfizer's JAK inhibitor Xeljanz as well as injected biologics such as Amgen Inc's Enbrel and AbbVie's Humira.

Humira generated more than $16 billion in sales last year, but competition is looming. AbbVie is trying to block the launch of an FDA-approved biosimilar, made by Amgen, arguing that its patents on Humira offered protection until at least 2022.

AbbVie is also evaluating upadacitinib for several other autoimmune conditions, including psoriatic arthritis, Crohn's disease and ulcerative colitis.

Holford estimated peak sales of $3.5 billion for the drug across all diseases. Pfizer's Xeljanz generated sales of $927 million last year.

(This story corrects paragraph 3 to clarify that Xeljanz is the only U.S.-approved JAK inhibitor.)

(Reporting by Divya Grover in Bengaluru, additional reporting by Natalie Grover; Editing by Sai Sachin Ravikumar and by Savio D'Souza)

VIENTIANE Dozens of fertility clinics have mushroomed in land-locked Laos after scandals over commercial surrogacy have spurred wealthier southeast Asian neighbors to ban the controversial procedure since 2015.

ZURICH Novartis on Wednesday touted new data from its T-cell therapy CTL019, saying it is on a par with results of experimental molecules from Kite Pharma and Juno Therapeutics that also target aggressive blood cancers.

Here is the original post:
AbbVie's rheumatoid arthritis drug succeeds in trial - Reuters

Read More...

Arthritis symptoms – painful joints could be a sign of THIS life-threatening condition – Express.co.uk

June 8th, 2017 1:41 am

GETTY

Osteoarthritis affects around 4 million people in the UK every year.

When a joint develops osteoarthritis, some of the cartilage covering the ends of the bones gradually roughens and becomes thin, and the bone underneath thickens.

Rheumatoid arthritis is a serious and disabling autoimmune disease in which the immune system mistakenly attacks and destroys healthy body tissue.

It affects more than 690,000 people in the UK, of which over 500,000 are women and around three-quarters are of working age.

GETTY

However there is one form of arthritis - which occurs most commonly in the knees and hips.

Septic arthritis is the inflammation of a joint which is caused by a bacterial infection.

It is also known as bacterial arthritis, or even infections arthritis.

Any joint can be affected by the condition but it occurs most frequently in the knees and hips. However there is one form of arthritis - which occurs most commonly in the knees and hips.

GETTY

Septic arthritis is the inflammation of a joint which is caused by a bacterial infection.

It is also known as bacterial arthritis, or even infections arthritis.

Any joint can be affected by the condition but it occurs most frequently in the knees and hips. There are number of factors which can increase the risk of developing the condition, including having joint surgery, such as a knee replacement or hip replacement, having a bacterial infection somewhere else in your body and having a long term condition.

Having rheumatoid arthritis can increase the risk of developing the condition.

Experts also warn that using injected drugs, or medication which suppresses the immune system can also be a factor.

Getty

1 of 12

Septic arthritis typically causes severe pain

Invasive bacterial infections caused by Staphylococcus aureus and Streptococcus pyogenes bacteria can be life-threatening and fatal, causing sepsis - blood poisoning, pneumonia and Toxic Shock Syndrome.

The bacteria, which normally lives harmlessly on the skin, nose or mouth but can invade the bodys bloodstream and release poisonous toxins.

Toxins can damage tissue skin and organs and can disturb vital organ functions.

If doctors suspect pain could be a symptom of septic arthritis, GPs are likely to refer patients to A&E, where they will give patients a blood test.

The condition is usually treated with antibiotics and often fluid will have to be drained from one of the affected joints.

More here:
Arthritis symptoms - painful joints could be a sign of THIS life-threatening condition - Express.co.uk

Read More...

Play a round of golf, help people living with arthritis – KTVA.com – Anchorage, Alaska

June 8th, 2017 1:41 am

Estimated read time

1m 24s

A golf tournament happening on the summer solstice is raising money to benefit the nonprofit Arthritis Foundation Alaska.

There are about 125,000 peoplewith arthritis living in Alaska, including 900 children, accordingto the Arthritis Foundation.

It was real obvious to me that they were the underdog when it came to charities, said Kevin Turkington, owner of Midnight Sun Homecare, a sponsor of the Midnight Sun Charity Golf Classic. We have kind of become family in this effort to help people understand that its not your grandmothers disease anymore.

There are many different types of arthritis, but its commonly referred to joint pain or joint disease. Symptoms of arthritis include swelling, pain, stiffness and decreased range of motion, according to the Arthritis Foundation. It is a disability that can change a persons way of life.

You dont just take a couple aspirin and everything is fine, Turkington said. its like your joints become your enemy and it attacks them.

The Arthritis Foundation Alaska helps fund research, public health programs and advocacy. Last year more than 2,600 Alaska relied on the foundation as atool, according to its website.

The money raised at the 2017 Midnight Sun Charity Golf Classicwill go to the foundation.

Eighty-two percent of all the funds raised go directly to finding a cure and supporting those who suffer, and here in Alaska, Turkington said. Which is unheard of in the nonprofit world where mostly 30 percent goes to admin-type costs.

Midnight Sun Charity Golf Classic Swing into Solstice

Visit link:
Play a round of golf, help people living with arthritis - KTVA.com - Anchorage, Alaska

Read More...

Arthritis and Your Weight Have More of a Connection Than You Think – Noozhawk

June 8th, 2017 1:41 am

By Cottage Health | June 7, 2017 | 9:30 a.m.

Few of us need to be given more reasons to drop those extra pounds. We could do it for our hearts or our chins, for lower medical bills or freer spirits.

But did you know you should also do it for your joints?

Being overweight increases your risk of degenerative arthritis in the weight-bearing joints, especially the knees, said Dr. Victor Tacconelli, an orthopedic surgeon affiliated with Cottage Health.

According to the U.S. Surgeon Generals Office, your odds of developing osteoarthritis (OA) the most common type of the disease increase by 9 percent to 13 percent for every two-pound increase in weight.

In other words, being 20 pounds overweight doubles your chances of getting arthritis.

Conversely, losing just 12 pounds halves the risk of osteoarthritis for overweight women, according to Dr. David Felson, the former director of the Boston University Arthritis Center and currently a professor at Boston University School of Medicine.

There is no doubt that being overweight contributes to getting osteoarthritis and to making it worse, he told Arthritis Today magazine.

The extra weight is especially hard on the knees, since every extra pound you carry adds a three- or four-pound load to each knee, Felson says.

Study after study has established the link between being overweight or obese and having arthritis in the hips or knees. According to one study, obese women were nearly four times as likely as nonobese women to develop osteoarthritis of the knee, and the risk for obese men was nearly five times greater.

In fact, the U.S. Centers for Disease Control and Prevention reports that 66 percent of people with arthritis are overweight or obese.

If you already have osteoarthritis, doctors say that losing just a few pounds can significantly decrease your pain, not to mention lower your chances of developing OA in other weight-bearing joints.

Remember, for every pound you lose, its like taking four pounds of load off each knee every time you take a step.

One problem is that osteoarthritis often makes it painful to exercise, leading many sufferers to avoid physical activity and put on even more weight. But low-impact exercises, like water aerobics and bicycling, can help your sore joints and relieve stiffness and swelling.

Read the rest here:
Arthritis and Your Weight Have More of a Connection Than You Think - Noozhawk

Read More...

Gymnast, 12, flies high in spite of living with juvenile arthritis | Real … – Omaha World-Herald

June 8th, 2017 1:41 am

With each jump on the trampoline, Katie Chipman soared a little higher.

The creaks of springs and the thunk of her feet hitting the trampoline echoed through the quiet gym. After half a dozen jumps, the 12-year-old threw out the tricks.

Flips, spirals, twists.

When her turn was done, she sat on the sideline, applauding and cheering on her teammates.

But seven years ago, that scene was unthinkable. Diagnosed with juvenile arthritis, Katie couldnt stand or walk, let alone compete in gymnastics.

One in every 250 children in the United States is affected by variations of the disease, according to the Arthritis Foundation.

Katies parents noticed the problem when she was 5. It started with fevers, muscle aches and a rash on her legs. The symptoms would come and go during the day and leave her exhausted. All she did was sleep.

Within a week, Katies mom took her to the familys pediatrician at Offutt Air Force Base. Katies father, Todd Chipman, was stationed there while in the Navy.

The pediatrician diagnosed Katie with a virus.

While a normal virus will run its course, this one only got worse.

I knew something wasnt right with my kid. It wasnt just a cold, her mom, Kim Chipman, said.

The Papillion family went to urgent care. Doctors there gave Katie a steroid shot that alleviated symptoms for a few days before they returned.

Almost a month after her first visit, Katie and her mom returned to the doctors office on base. After a barrage of tests, they had an answer: systemic juvenile idiopathic arthritis. That type of the disease is characterized by a spiking fever and rash.

No one in the family, including Katies twin sister, had arthritis.

I remember I looked at the doctor and said, Can we go back to mystery virus instead of this? This diagnosis is her whole life, Chipman said. It was certainly something we had to wrap our heads around.

Katie had to give up gymnastics, and she couldnt sit on the floor with kindergarten classmates, because it would be too hard to get back up.

Katies pediatric rheumatologist put her on steroids to curb inflammation. The drugs doubled the girls weight. Doctors struggled to find a medication to keep arthritis symptoms at bay without introducing a different problem.

Katie tried at-home injections, but that didnt sufficiently calm the arthritis. About a year and a half into her diagnosis, Katie started twice-a-month infusion treatments at Childrens Hospital & Medical Center.

Administered through an IV, the treatments ease Katies symptoms without introducing new side effects. Each appointment takes about four hours.

That medication is like gold for her, Kim Chipman said. It gave her her life back.

There is a risk that shell stop responding to the treatment. But theres also a slight chance that her symptoms may lessen enough to allow her to get off medication altogether.

Katies type of arthritis accounts for 10 percent of the arthritis seen in children nationally, said Dr. Adam Reinhardt, a pediatric rheumatologist at Childrens Hospital & Medical Center.

For many arthritis patients, gymnastics would be out of the question because the sport requires so much joint activity, Reinhardt said. But infusion treatments have significantly limited the symptoms of her disease.

The fact that she has responded this well to therapy and gone on to be a high-level gymnast and tumbler is impressive, Reinhardt said.

Staying active is important for adults and children diagnosed with arthritis.

Katie started gymnastics while the family was living in Hawaii. Chipman home-schooled her four children, and they did gymnastics for physical education. The other children stopped participating in the sport after moving to Papillion eight years ago.

But Katie wanted to continue. She competes on a trampoline and tumbling team through Airborne Academy near 111th and Q Streets.

At a recent regional competition, Katie took first in the trampoline category. She placed third in the double mini category another trampoline exercise and sixth in tumbling. At the end of the month, shell compete with her teammates at nationals in Milwaukee.

I want to do it because its fun, Katie said. I want to put time and effort into it, because I want to compete well.

When patients like Katie have flares of the disease, they need to take it easy and manage the pain. When Katie has a flare-up, the original symptoms fever, rash and joint pain return.

Its kind of like a freight train. It takes awhile to get going, but once it does, its hard to stop, her mom said.

Katie's gymnastics coach, Tex Womack, said its up to Katie to speak up at the gym if shes hurting.

Womack, whos been working with Katie since August, didnt know about her arthritis until she missed a few practices. He said she rarely mentions the topic in the gym.

Shes a real tough athlete, he said. She doesnt make a big deal of it to me.

Katie, who will start eighth grade at Papillion Middle School in the fall, doesnt want the disease to make her different.

I just have to go through it sometimes, because I dont like to sit out, Katie said. I like to be like everyone else and like a normal kid.

At a recent practice, Katie got a running start before launching herself onto a trampoline. She jumped once and did a back flip before gaining momentum and height. After two more back flips, she landed gingerly in a pit of foam squares.

Thats all you ever want for your kids: to be able to do what they love, Chipman said. Were very thankful weve found something that works.

kelsey.stewart@owh.com, 402-444-3100,twitter.com/kels2

Visit link:
Gymnast, 12, flies high in spite of living with juvenile arthritis | Real ... - Omaha World-Herald

Read More...

Bioquark Hopes to Bring Dead Back to Life Using Stem Cell Therapy – India West

June 8th, 2017 1:40 am

A Philadelphia-based company along with an Indian orthopedic surgeon has said it will start a new type of stem cell therapy that claims it can bring people back from the dead.

Bioquark, led by chief executive Ira Pastor, said it will begin conducting trials of the therapy later in the year in an undisclosed country in Latin America, according to a New York Post report.

Pastor and Indian orthopedic surgeon Himanshu Bansal had initially hoped to run tests in India in 2016 but the Indian Council of Medical Research pulled the plug on their plans and asked them to take the trials elsewhere, the Post reported.

Most countries officially declare someone dead when there is irreversible loss of brain function. The Bioquark therapy boasts it can reboot the brain.

The company said it will begin testing on humans, with no plans to experiment on animals.

Scientists plan to examine individuals aged between 15 and 65 who have been declared brain dead from a traumatic brain injury, the report noted, citing a published study.

The three-stage process starts with harvesting stem cells from the patients own blood before injecting them back into their body. Next, the patient is given a dose of peptides injected into their spinal cord. The final step is a 15-day course of laser and median nerve stimulation while monitoring the patient with MRI scans.

Bansal practices in New Delhi.

Read the rest here:
Bioquark Hopes to Bring Dead Back to Life Using Stem Cell Therapy - India West

Read More...

Plant genetics Branching out for crop improvement – Nature.com

June 6th, 2017 11:48 pm

Nature.com
Plant genetics Branching out for crop improvement
Nature.com
Inflorescence architecture is the arrangement of flowers and their underlying stem branching patterns, and it has important effects on the yield of the fruits or grains from agricultural plants. A new study dissects key genetic underpinnings of tomato ...

See more here:
Plant genetics Branching out for crop improvement - Nature.com

Read More...

New CEO for tilapia genetics firm – Fish Update

June 6th, 2017 11:48 pm

GENOMAR Genetics, which specialises in the tilapia industry, has appointed Alejandro Tola Alvarez as its CEO.

Alvarez (pictured), who took up his new role on June 1, will be responsible for innovation, operations and business development within the company, which is part of the EW Group.

He hasbeen part of the Genomar group since 2006, based in South-East Asia as chief operational officer and in Norway as chief technical officer.

We were very pleased to find a highly qualified internal candidate for the CEO position, said chairman Odd Magne Rdseth.

Alejandro has played a major role in both R&D and commercial development of the most reputable and professional genetic brands in global tilapia aquaculture.

He comes with a deep understanding of the tilapia operating environments and the opportunities of modern breeding technologies, such as genomics, to improve economic and environmental performance of the industry.

Alvarez is a qualified vet and has masters degrees in aquaculture and business administration.

GenoMar Genetics, based in Oslo with its main operation in Luzon, Philippines, has developed the Genomar Supreme Tilapia strain (GST) through more than 25 years of selective breeding.

The company was part of the Norway Fresh Group until March 2017 when EW Group concluded an agreement to acquire 100 per cent of GenoMar Genetics shares.

EW Group, based in Visbek, Germany, is a family owned holding company with more than 120 subsidiaries in over 30 countries.

The core business of the group, which has 9,000 employees worldwide, is animal breeding, animal nutrition and animal health.

Over the past 10 years, the group has expanded into the aquaculture sector and includes companies such as AquaGen, Aquabel, GenoMar Genetics and Vaxxinova.

Read the rest here:
New CEO for tilapia genetics firm - Fish Update

Read More...

Why Herbalife, JinkoSolar, and NewLink Genetics Slumped Today … – Motley Fool

June 6th, 2017 11:48 pm

The stock market closed Monday with modest losses, sending the Dow, S&P 500, and Nasdaq Composite lower from their record closes last Friday. Nevertheless, the declines were all less than 0.2%, and investors appeared to be in a wait-and-see mode as they look forward to more momentous news due out later this month. Among the top potential market movers for June will be the U.K. elections later this week and the Federal Reserve's meeting to determine the future course of interest rates. Yet company-specific items were in the spotlight today, and some stocks posted significant losses. Herbalife (NYSE:HLF), JinkoSolar (NYSE:JKS), and NewLink Genetics (NASDAQ:NLNK) were among the worst performers on the day. Below, we'll look more closely at these stocks to tell you why they did so poorly.

Shares of Herbalife dropped nearly 7% after the company said this morning that it would have to revise its financial expectations. Citing the need for its distributors to learn, teach, and implement new technology and processes, Herbalife said that it now expects net sales to fall 2% to 6% in the second quarter, with volume falling 4% to 8%. For the full year, Herbalife thinks it will be able to grow revenue 0.5% to 3.5% despite seeing volume come in a range between -1% and +2%. Upward adjustments to earnings guidance weren't enough to satisfy shareholders, and activist investor Bill Ackman spoke out against the company's news. Herbalife is a controversial company, but when negative things that get said about the business pan out in its financials, the seller of nutritional supplements and other consumer products needs to take steps to remedy the situation.

Image source: Herbalife.

JinkoSolar stock fell 8% in the wake of the company's first-quarter financial results. The Chinese solar company said that solar shipments jumped by nearly 30% from year-ago levels, topping the 2-gigawatt mark. Revenue was also up by double-digit percentages, but adjusted net income was down sharply, falling more than 80%. CEO Kangping Chen said that falling selling prices of solar modules led to gross margin contraction, which in turn resulted in bottom-line weakness. Chen remained optimistic about JinkoSolar's prospects for the remainder of the year, but investors didn't seem as confident that the company would be able to improve margins and capitalize on building demand in China. With JinkoSolar having been involved in big projects in the Persian Gulf region, it's possible that diplomatic tensions in the area also weighed on the stock.

Finally, shares of NewLink Genetics finished down 12%. The company said over the weekend that a phase 2 study of its breast cancer candidate treatment indoximod in combination with taxane chemotherapy failed to reach its intended endpoints. In particular, NewLink was trying to establish a statistically significant difference as to progression-free survival, overall survival, and objective response rate. Without achieving those goals, investors aren't certain what the next step forward is for NewLink. Still, with other studies having shown more encouraging results, NewLink might still end up being a potential takeover target from larger players in the biotech space.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Read the rest here:
Why Herbalife, JinkoSolar, and NewLink Genetics Slumped Today ... - Motley Fool

Read More...

Oxford Genetics gets 500000 from Mercia Technologies – Tech City News

June 6th, 2017 11:48 pm

BioTech firm Oxford Genetics has raised 500,000 from Mercia Technologies.

The news comes after the company, which specialises in synthetic biology and DNA design, raised 1m from Mercia, which has a direct equity stake of 47.9% in the firm in October last year.

Oxford Genetics has so far raised 5.8m through a combination of grants and external investments and says it will use this latest round to expand its reach in the US market and further its growth.

Oxfords AI firm Oxbotica gets 8.6m to lead driverless car consortium

Dr Ryan Cawood, CEO of Oxford Genetics, commented on the raise: Mercias continued support has been instrumental in helping us to achieve the significant progress to date.

Our turnover has doubled in the last year and with this additional capital, we will be able to further expand the team, giving us the ability to build the most innovative technologies in the DNA and protein design market.

Dr Mark Payton, CEO of Mercia Technologies PLC, spoke about the companys trajectory over the past year.

Oxford Genetics has clearly demonstrated its ability to create market leading technologies and has been bolstered by an industry leading research and development team.

Payton went on to note that life sciences and bio-sciences continued to be a key sector for Mercia and one which they believe would deliver significant shareholder value over the medium term.

Follow Yessi Bello Perez on Twitter @yessibelloperez

Read this article:
Oxford Genetics gets 500000 from Mercia Technologies - Tech City News

Read More...

What’s In Your Genes? – Pacific Northwest Inlander

June 6th, 2017 11:47 pm

Picture a time in the not-too-distant future when whole genome sequencing is routine. A time when, before babies even learn to talk, their parents will have the ability to learn what the future may have in store for their offspring: Is their little girl predisposed to getting breast cancer? Will their happy-go-lucky son one day develop Alzheimer's?

"There is no doubt in my mind that, in addition to going in and having blood chemistry done, you're gonna have DNA sequencing done, too. It will be there at some point," says Nicholas Schork, a quantitative geneticist at the J. Craig Venter Institute in La Jolla, California, who has studied genomic medicine for more than three decades. "We can debate about the timeline, but it'll become routine."

The hope is that genetic testing will make health care more effective by allowing doctors and patients to focus on areas that need attention the patient's genetic "vulnerabilities." At the same time, patients may learn of areas where they won't need to be quite as vigilant. And treatments could, in turn, be perfectly tailored to a patient's specific needs.

But as with any significant and broadly applicable medical advance, there are questions. For example, should patients learn that they carry markers for currently incurable genetic diseases, or that they are at high risk for developing a condition like Alzheimer's, which has no effective treatment? And just who owns all that genetic data? Who will have access to it?

Even with important questions left unanswered, health educators are moving forward to take advantage of the promises genetic testing offers. Washington State University's new Elson S. Floyd College of Medicine has announced it is partnering with Arivale, a Seattle-based company that conducts whole genome sequencing, to help complete a portrait of a person a "portrait" that can be used to promote wellness over that individual's entire lifespan. Every member of the school's inaugural class will have the opportunity to undergo testing, which will also include blood tests and a lifestyle evaluation. Then, over the next year, Arivale's team of nurses and dietitians will provide individually tailored follow-up, based on each individual's risks and goals. It's a unique partnership, made possible in large part because the medical school is new, with its first class of students starting in 2017.

Allowing the medical students to experience genetic testing firsthand is just part of the goal. "We need physicians that understand it well enough that they can make it better going forward," says John Tomkowiak, founding dean of WSU's College of Medicine. "That's where our students are going to be uniquely positioned."

WHAT GENES TELL US

Genetic testing already provides important information about a person's health or their heritage. Hospitals screen newborn babies for certain genetic disorders, and in some cases, tests can detect disorders before birth. And diagnostic testing can confirm, or rule out, many disorders in adults.

Testing doesn't have to be ordered by a physician. For $200, you can provide a saliva sample, mail it back to 23andMe.com and find out not only your ancestry, but also your risks for a number of diseases, including Alzheimer's and Parkinson's. Ancestry.com offers a glimpse into your heritage for $99. Color.com claims to reveal your risk for the most common hereditary cancers, and even offers "complimentary genetic counseling" for a $249 fee.

But if genetic testing is to revolutionize the health care industry, as many have promised, there's still a ways to go. "The technology is at the beginning stages," says Thomas May, a faculty researcher for the HudsonAlpha Institute for Biotechnology.

Companies like 23andMe offer genetic tests that may provide information about some genetic disorders from currently known genetic variants. But whole genome sequencing is different; it will reveal all your individual genetic variants.

How valuable is that information? There are a relatively small number of conditions that researchers are confident result from a specific genetic variant, May says. For example, there is one variant that researchers have found is associated with an increased risk of developing breast or ovarian cancer. A genetic test that shows an increased risk for breast cancer is considered an "actionable" outcome, meaning there are things you can do to prevent the outcome, like beginning mammograms earlier. Though there are more than 50 actionable outcomes like that, it's still a relatively small number.

Adding to the confusion is the fact that not everyone who develops breast cancer actually has the genetic variant in fact, May says only about 10 percent do. So even if testing shows that you don't have the "breast cancer gene," that doesn't mean it's OK to stop getting mammograms.

"Most variants and correlations are of that type: We can't say for certain if you're gonna get a disease," May says.

Doctors are mixed about whether genetic testing is currently having a real impact on patients. In a May survey conducted by the Medscape Physician Oncology Report on Genomics Testing, 71 percent of oncologists surveyed felt that genetic testing was either "very" or "extremely" important to the oncology field. At the same time, 61 percent said that, currently, fewer than a quarter of their patients would actually benefit from genetic testing.

The number of diseases with "actionable" outcomes will inevitably grow, as more people are tested and more data becomes available. But this leaves deeper questions, says Schork, the quantitative geneticist. A company or health care provider would likely give patients information about diseases that can be prevented or cured. If someone is predisposed to obesity, for instance, then he or she can elect to receive targeted care to reduce that risk.

But what about diseases that, right now, are incurable?

Take Huntington's disease, a genetic disorder that breaks down nerve cells in the brain. It's rare, but it's a "hideous way to die," Schork says. A person can be screened at the age of 25 and be found to carry the Huntington's gene, but there's debate about whether or not that information should be shared with a client or not. The same goes for genetic variants related to Alzheimer's disease.

"If there's nothing they can do about it, then there's a concern about whether or not that information should be imparted," Schork says.

When the Food and Drug Administration ordered 23andMe to stop telling customers their odds of contracting diseases in 2013, Harvard Medical School genetics professor Robert Green and Laura Beskow, a professor at Duke University's Institute for Genome Sciences and Policy, argued against the FDA. They cited a number of studies showing that direct-to-consumer genetic testing does not cause a large percentage of customers despair. In an interview with the New York Times in April, Green said the potential for distress based on results of a genetic test for Alzheimer's was "much smaller than anticipated."

Another question: Who really owns the DNA data that is being collected from willing users of genetic testing? Consider Myriad, a company that offers genetic testing both to help determine cancer risk and design better treatment plans for patients who already have cancer. The company has something that "others do not," Schork says: insight into which genetic variants predispose women to breast cancer.

What Myriad is really selling, then, is not the genetic test itself, but access to insights it has gained through mining its database, insights that can be leveraged into whatever level of payment the company decides to charge.

It's potentially critical information that could help save a life, and some argue that the data should be in the public domain not held by a private company.

"There have been huge debates about whether the community should challenge the monopoly that Myriad has," Schork says. "There are many groups out there that would like to counteract the monopoly Myriad has, by building public domain data sets."

JUST ONE TOOL

"Genetic testing is not a blueprint. It's really not," says Jennifer Lovejoy, chief translational science officer for Arivale. "Genes are really just one factor the environment, diet, exercise, pollutants and even emotional state have a big impact on genes."

That's why Arivale not only collects genetic information on each client, but also evaluates various blood tests and lifestyle factors to create a "dense data cloud" of information about a patient.

"That is the grand vision: that everybody would have these dense, dynamic data clouds, and understand the choices that will be optimal to optimize wellness and avoid disease," says Lovejoy.

Arivale touts the success stories among its nearly 2,000 clients. One client found out he had a gene associated with high sensitivity to saturated fat, giving him a better indication of an appropriate diet that helped him lose weight. Another client discovered that his genes may have an impact on his cholesterol. Another learned he was at risk of developing diabetes.

Ideally, this type of preventive care will soon be covered by insurance, Lovejoy says. The thinking is that preventing disease will bring down the cost of health care overall, making insurers likely to cover more preventive care, "but we have to prove it," Lovejoy says. Researchers are conducting studies and trials to do just that, and if they can prove it, then genetic testing could soon be routine in health care.

"If you think about what health care should mean, it should mean, one, the ability to deal with disease and that's what everyone does today," Arivale co-founder Leroy Hood said at a press conference in April announcing the company's partnership with WSU. "But two, it should mean the ability to optimize wellness for each individual. That is, improving their health and/or letting them avoid disease." That's a concept Hood calls "scientific wellness, and he thinks it could lead to "a whole new health care industry in the future."

Tomkowiak, of WSU's College of Medicine, agrees: "The concept of scientific wellness has the potential to disrupt the entire industry by shifting the cost curve, by keeping people healthier and reducing the cost of health care overall."

Regardless of whether or not Arivale becomes an industry leader, Tomkowiak believes that the practice of medicine will be fundamentally altered in the near future.

"We absolutely believe that seven years from now, the practice of scientific medicine and scientific wellness will be common," he says. "Instead of being behind the curve, we want... to be leading this effort."

For about $3,500, clients can sign up for Arivale's program. The fee includes whole genome sequencing, which is also available from other sources. So how do Arivale clients achieve "scientific wellness"? Here are the elements of their program:

Welcome package: Clients get a welcome package with a Fitbit to track sleep, activity and heart rate. The package asks for information to help understand a client's bacteria in their gut, and asks for a sample of saliva to measure a person's stress level.

Online test: Clients take a series of online assessments about their goals, health history, lifestyle, stress, personality and happiness.

Call from coach: You'll talk to a coach who will get to know what you want to accomplish and give you a personalized action plan.

Labs: You'll take blood tests so your coach can understand your current health. While you're there, they'll take your vital signs.

A picture emerges: The various test create a picture of you, which an Arivale coach will use to provide a step-by-step plan to "optimize your wellness," according to the company.

Follow-up: You're not done yet. You'll be contacted by your coach regularly to review your action plan, and Arivale will provide reports on how you're progressing. Every six months, you'll complete another set of clinical labs.

Source: arivale.com/your-journey

Read more here:
What's In Your Genes? - Pacific Northwest Inlander

Read More...

New cancer medicine targets rare genetic flaw – Press TV

June 6th, 2017 11:47 pm

This file photo shows doctors at Memorial Sloan Kettering Cancer Center in New York City.

An experimental cancer medicine called larotrectinib has shown promise treating a diverse range of cancers in people young and old, researchers said at a major cancer conference in the United States.

The treatment targets a genetic abnormality which is often found in rare cancers - including salivary gland cancer, juvenile breast cancer, and a soft tissue cancer known as infantile fibrosarcoma - which are particularly difficult to treat.

This abnormality also occurs in about 0.5 percent to one percent of many common cancers.

In the study released at the American Society of Clinical Oncology conference, 76 percent of cancer patients - both children and adults with 17 different kinds of cancer - responded well to the medicine.

A total of 79 percent were alive after one year. The study is ongoing.

Twelve percent went into complete remission from their cancer.

The clinical trial included 55 patients - 43 adults and 12 children. All had advanced cancers in various organs, including the colon, pancreas and lung, as well as melanoma.

"These findings embody the original promise of precision oncology: treating a patient based on the type of mutation, regardless of where the cancer originated," said lead study author David Hyman, chief of early drug development at Memorial Sloan Kettering Cancer Center in New York.

"We believe that the dramatic response of tumors with TRK fusions to larotrectinib supports widespread genetic testing in patients with advanced cancer to see if they have this abnormality."

Made by Loxo Oncology Inc., larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) fusion proteins.

TRK proteins are a product of a genetic abnormality when a TRK gene in a cancer cell fuses with one of many other genes, researchers said.

The US Food and Drug Administration has not yet approved the treatment for widespread use.

The treatment was well tolerated by patients, and the most common side effects were fatigue and mild dizziness.

"If approved, larotrectinib could become the first therapy of any kind to be developed and approved simultaneously in adults and children, and the first targeted therapy to be indicated for a molecular definition of cancer that spans all traditionally-defined types of tumors," said Hyman.

(Source:AFP)

Read more:
New cancer medicine targets rare genetic flaw - Press TV

Read More...

The Future of Medicine Depends on Protections for Pre-Existing Conditions – Pacific Standard

June 6th, 2017 11:47 pm

Pacific Standard
The Future of Medicine Depends on Protections for Pre-Existing Conditions
Pacific Standard
Biomedical researchers can see a future where genetic tests are used to treat and prevent many diseases before major symptoms even present themselves. But that future won't be possible without strong insurance protections for pre-existing conditions.

View post:
The Future of Medicine Depends on Protections for Pre-Existing Conditions - Pacific Standard

Read More...

Drug Helps Fight Breast Tumors Tied to ‘Cancer Genes’ – Sioux City Journal

June 6th, 2017 11:47 pm

SUNDAY, June 4, 2017 (HealthDay News) -- A twice-daily pill could help some advanced breast cancer patients avoid or delay follow-up sessions of chemotherapy, a new clinical trial reports.

The drug olaparib (Lynparza) reduced the chances of cancer progression by about 42 percent in women with breast cancer linked to BRCA1 and BRCA2 gene mutations, according to the study.

Olaparib delayed cancer progression by about three months. The drug also caused tumors to shrink in three out of five patients who received the medication, the researchers reported.

"Clearly the drug was more effective than traditional chemotherapy," said Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society.

"This is a group where a response is more difficult to obtain -- a young group with a more aggressive form of cancer -- and nonetheless we saw a close to 60 percent objective response rate," he said.

The study was funded by AstraZeneca, the maker of Lynparza.

Olaparib works by cutting off the avenues that malignant cancer cells use to stay alive, said lead researcher Dr. Mark Robson. He's a medical oncologist and clinic director of Clinical Genetics Service at Memorial Sloan Kettering Cancer Center in New York City.

The drug inhibits PARP, an enzyme that helps cells repair damaged DNA, Robson said.

Normal cells denied access to PARP will turn to the BRCA genes for help, since they also support the repair of damaged DNA, Robson said.

But that "backup capability" is not available to breast cancer cells in women with BRCA gene mutations, Robson said.

"When you inhibit PARP, the cell can't rescue itself," Robson said. "In theory, you should have a very targeted approach, one specifically directed at the cancers in people who have this particular inherited predisposition."

Olaparib already has been approved by the U.S. Food and Drug Administration for use in women with BRCA-related ovarian cancer. Robson and his colleagues figured that it also should be helpful in treating women with breast cancer linked to this genetic mutation.

The study included 302 patients who had breast cancer that had spread to other areas of their body (metastatic breast cancer). All of the women had an inherited BRCA mutation.

They were randomly assigned to either take olaparib twice a day or receive standard chemotherapy. All of the patients had received as many as two prior rounds of chemotherapy for their breast cancer. Women who had hormone receptor-positive cancer also had been given hormone therapy.

After 14 months of treatment, on average, people taking olaparib had a 42 percent lower risk of having their cancer progress compared with those who received another round of chemotherapy, Robson said.

The average time of cancer progression was about seven months with olaparib compared with 4.2 months with chemotherapy.

Tumors also shrank in about 60 percent of patients given olaparib. That compared with a 29 percent reduction for those on chemotherapy, the researchers said.

Severe side effects also were less common with olaparib. The drug's side effects bothered 37 percent of patients compared with half of those on chemo. The drug's most common side effects were nausea and anemia.

"There were fewer patients who discontinued treatment because of toxicity compared to those who received chemotherapy," Robson said. "Generally it was pretty well tolerated."

Only about 3 percent of breast cancers occur in people with BRCA1 and BRCA2 mutations, the researchers said in background notes.

Despite this, the results are "quite exciting," said Dr. Julie Fasano, an assistant professor of hematology and medical oncology at the Icahn School of Medicine at Mount Sinai in New York City.

Olaparib could wind up being used early in the treatment of metastatic breast cancer as an alternative to chemotherapy, and future studies might find that the drug is effective against other forms of breast cancer, Fasano said.

"It may be a practice-changing study, in terms of being able to postpone IV chemotherapy and its associated side effects" like hair loss and low white blood cell counts, Fasano said.

Lichtenfeld noted that olaparib also places less burden on patients.

"It may be easier for women to take two pills a day rather than go in for regular chemotherapy," Lichtenfeld said. "Clearly, this is a treatment that will garner considerable interest.

The findings were scheduled to be presented Sunday at the American Society of Clinical Oncology's annual meeting, in Chicago. The study was also published June 4 in the New England Journal of Medicine.

Go here to see the original:
Drug Helps Fight Breast Tumors Tied to 'Cancer Genes' - Sioux City Journal

Read More...

Scientists are finding more genes linked to IQ. This doesn’t mean we can predict intelligence. – Vox

June 6th, 2017 11:47 pm

Last month, researchers announced some astonishing findings in Nature Genetics: Theyd found 40 genes that play a role in shaping human intelligence, bringing the total number of known intelligence genes up to 52.

This study was a big deal because while weve known intelligence is largely heritable, we havent understood the specifics of the biology of IQ why it can be so different between people, and why we can lose it near the end of life.

The Nature Genetics study was a key early step toward understanding this, hailed as an enormous success in the New York Times.

And there are many more insights like this to come. The researchers used a design called a genome-wide association study. In it, computers comb through enormous data sets of human genomes to find variations among them that point to disease or traits like intelligence. As more people have their genomes sequenced, and as computers become more sophisticated at seeking out patterns in data, these types of studies will proliferate.

But theres also a deep uneasiness at the heart of this research it is easily misused by people who want to make claims about racial superiority and differences between groups. Such concerns prompted Nature to run an editorial stressing that the new science of genetics and intelligence comes to no such conclusions. Environment is crucial, too, Nature emphasized. The existence of genes for intelligence would not imply that education is wasted on people without those genes. Geneticists burned down that straw man long ago.

Also, nothing in this work suggests there are genetic difference in intelligence when comparing people of different ancestries. If anything, it suggests that the genetics that give rise to IQ are more subtle and intricate than we can ever really understand.

Were going to keep getting better at mapping the genes that make us smart, make us sick, or even make us lose our hair. But old fears and myths about genetics and determinism will rear their heads. So will fears about mapping ideal human genes that will lead to designer babies, where parents can pick traits for their children la carte.

To walk through the science, and to bust its myths, I spoke to Danielle Posthuma, a statistical geneticist at Vrije Universiteit in Amsterdam, who was the senior author on the latest Nature study.

Theres a simple understanding of genetics were all taught in high school. We learn, as Gregor Mendel discovered with pea plants, that we can inherit multiple forms of the same gene. One variation of the gene makes wrinkled peas; the other makes for round peas. Its true, but its hardly the whole story.

In humans, a few traits and illnesses work like this. Whether the bottom of your earlobes stick to the side of your face or hang free is the result of one gene. Huntingtons disease which deteriorates nerve cells in the brain is the result of a single gene.

But most of the traits that make you you your height, your personality, your intellect arise out of a complex constellation of genes. There might be 1,000 genes that influence intelligence, for example. Same goes for the genes that lead to certain disorders. Theres no one gene for schizophrenia, for obesity, for depression.

A single gene for one of these things also wont have an appreciable impact on behavior. If you have the bad variant of one gene for IQ, maybe your IQ score ... is 0.001 percent lower than it would have been, Posthuma says.

But if you have 100 bad variants, or 1,000, then that might make a meaningful difference.

Genome-wide association studies allow scientists to start to see how combinations of many, many genes interact in complicated ways. And it takes huge data sets to sort through all the genetic noise and find variants that truly make a difference on traits like intelligence.

The researchers had one: the UK Biobank, a library that contains genetic, health, and behavioral information on 500,000 Britons. For the study, they pulled complete genome information on 78,000 individuals who had also undergone intelligence testing. Then a computer program combed through millions of sites on the gene code where people tend to variate from one another, and singled out the areas that correlated with smarts.

The computer processing power needed for this kind of research this study had to crunch 9.3 million DNA letters from 78,000 people hasnt been available very long. But now that it is, researchers have been starting to piece together the puzzle that links genes to behaviors.

A recent genome-wide analysis effort identified 250 gene sites that predicted male pattern baldness in a sample of 52,000 men. (Would you really want to know if you had them?) And theres been progress identifying genes that signal risk for diabetes, schizophrenia, and depression.

And these studies dont just look at traits, diseases, and behavior. Theyre also starting to analyze genetic associations to life outcomes. A 2016 paper in Nature reported on 74 gene sites that correlate with educational attainment. (These genes, the study authors note, seem to have something to do with the formation of neurons.) Again, these associations are tiny the study found that these 74 gene variants could only explain 3 percent of the difference between any two people on what level of education they achieve. Its hardly set in stone that youll flunk school if you dont have these gene variants.

But still, they make a small significant difference once you start looking at huge numbers of people.

Its important to note that Posthumas study was only on people of European ancestry. Whatever we find for Europeans doesnt necessarily [extrapolate] for Asians or South Americans, [or any other group] she says. Those things are often misused.

Which is to say: The gene variations that produce the differences between Europeans arent necessarily the same variations that produce differences among groups of different ancestry. So if you were to test the DNA of someone of African origin, and saw they lacked these genes, it would be incredibly irresponsible to conclude they had a lower capacity for intelligence. (Again, there are also likely hundreds of more genetic sites that have something to do with intellect that have yet to be discovered.)

Posthumas work identifying genes associated with intelligence isnt about making predictions about how smart a baby might grow up to be. She doesnt think you can reliably predict educational or intelligence outcomes from DNA alone. This is all really about reverse-engineering the biology of intelligence.

Genes code for proteins. Proteins then interact with other proteins. Researchers can trace this pathway all the way up to the level of behavior. And somewhere along that path, there just might be a place where we can intervene and stop age-related cognitive decline, for instance, and Alzheimers.

We're finally starting to see robust reliable associations from genes with their behavior, she says. The next step is how do we prove that this gene is actually evolved in a disorder, and how does it work?

Understanding the biology of intelligence could also lead the way for personalized approaches to treating neurodegenerative diseases. Its possible that two people with Alzheimers may have different underlying genetic causes. Knowing which genes are causing the disease, then, you might be able to tailor the treatment, Posthuma says.

As more and more genome-wide studies are conducted, the more researchers will be able to assign people polygenic risk scores for how susceptible they might be for certain traits and diseases. That can lead to early interventions. (Or, perhaps in the wrong hands, a cruel and unfair sorting of society. Have you seen the movie Gattaca?)

And there are some worries about abusing this data, especially as more and more people get their genomes analyzed by commercial companies like 23&Me.

Many people are concerned that insurance companies will use it, she says. That they will look into people's DNA and say, Well, you have a very high risk of being a nicotine addict. So we want you to pay more. Or, You have a high risk of dying early from cancer. So you have to pay more early in life. And of course, that's all nonsense. Its still too complicated to make such precise predictions.

We now have powerful tools to edit genes. CRISPR/Cas9 makes it possible to cut out any specific gene and replace it with another. Genetic engineering has advanced to the point where scientists are building whole organisms from the ground up with custom DNA.

Its easy to indulge our imaginations here: Genome-wide studies are going to make it easier to predict what set of genes leads to certain life outcomes. Genetic engineering is making it easier to assemble whatever genes we want in an individual. Is this the perfect recipe for designer babies?

Posthuma urges caution here, and says this conclusion is far afield from the actual state of the research.

Lets say you wanted to design a human with superior intelligence. Could you just select the right variants of the 52 intelligence genes, and wham-o, we have our next Einstein?

No. Genetics is so, so much more complicated than that.

For one, there could be thousands of genes that influence intelligence that have yet to be discovered. And they interact with each other in unpredictable ways. A gene that increases your smarts could also increase your risk for schizophrenia. Or change some other trait slightly. There are trade-offs and feedback loops everywhere you look in the genome.

If you would have to start constructing a human being from scratch, and you would have to build in all these little effects, I think we wouldn't be able to do that, Posthuma says. It's very difficult to understand the dynamics.

There are about 20,000 human genes, made up of around 3 billion base pairs. We will never be able to fully predict how a person will turn out based on the DNA, she says. Its just too intricate, too complicated, and also influenced heavily by our environment.

So you could have a very high liability for depression, but it will only happen if you go through a divorce, she says. And who can predict that?

And, Posthuma cautions, there are some things that genome-wide studies cant do. They cant, for instance, find very, very rare gene variations. (Think about it: If one person in 50,000 has a gene that causes a disease, its just going to look like noise.) For schizophrenia, she says, we know that there's some [gene] variants that decrease or increase your risk of schizophrenia 20-fold, but they're very rare in the population.

And they cant be used to make generalizations about differences between large groups of people.

Last year, I interviewed Paul Glimcher, a New York University social scientist whose research floored me. Glimcher plans to recruit 10,000 New Yorkers and track everything about them for decades. Everything: full genome data, medical records, diet, credit card transactions, physical activity, personality test scores, you name it. The idea, he says, is to create a dense, longitudinal database of human life that machine learning programs can mine for insights. Its possible this approach will elucidate the complex interactions of genetics, behavior, and environment that put us at risk for diseases like Alzheimers.

Computer science and biology are converging to make these audacious projects easier. And to some degree, the results of these projects may help us align our genes and our environments for optimal well-being.

Again, Posthuma cautions: Not all the predictions this research makes will be meaningful.

Do we care if we find a gene that only increases our height or our BMI or our intelligence with less than 0.0001 percent? she asks. It doesn't have any clinical relevance. But it will aid our scientific understanding of how intellect arises nonetheless.

And thats the bottom line. The scientists doing this work arent in it to become fortune tellers. Theyre in it to understand basic science.

What most people focus on, when they hear about genes for IQ, they say: Oh, no. You can look at my DNA. You can tell me what my IQ score will be, Posthuma says. They probably dont know its much better if you just take the IQ test. Much faster.

Read more:
Scientists are finding more genes linked to IQ. This doesn't mean we can predict intelligence. - Vox

Read More...

New therapy offers hope against incurable form of breast cancer – The Guardian

June 6th, 2017 11:46 pm

A consultant studies a mammogram. The drug olaparib could slow cancer growth by three months, researchers have found. Photograph: Rui Vieira/PA

A type of inherited and incurable breast cancer that tends to affect younger women could be targeted by a new therapy, researchers have found.

A small study presented at the worlds largest cancer conference found treating patients with the drug olaparib could slow cancer growth by three months and be less toxic for patients with inherited BRCA-related breast cancer.

Researchers said there was not enough data to say whether patients survived longer as a result of the treatment.

We are in our infancy, said Dr Daniel Hayes, president of the American Society of Clinical Oncology and professor of breast cancer research at the University of Michigan. This is clearly an advance; this is clearly proof of concept these can work with breast cancer.

Does it look like its going to extend life? We dont know yet, he said.

The drug is part of the developing field of precision medicine, which targets patients genes to tailor treatment.

It is a perfect example of how understanding a patients genetics and the biology of their tumor can be used to target its weaknesses and personalize treatment, said Andrew Tutt, director of the Breast Cancer Now Research Centre at The Institute of Cancer Research.

Olaparib is already available for women with BRCA-mutant advanced ovarian cancer, and is the first drug to be approved that is directed against an inherited genetic mutation. The study was the first to show olaparib can slow growth of inherited BRCA-related breast cancer. The drug is not yet approved for that use.

People with inherited mutations in the BRCA gene make up about 3% of all breast cancer patients, and tend to be younger. The median age of women in the olaparib trial was 44 years old.

BRCA genes are part of a pathway to keep cells reproducing normally. An inherited defect can fail to stop abnormal growth, thus increasing the risk of cancer. The study examined the effectiveness of olaparib against a class of BRCA-related cancers called triple negative. Olaparib is part of a class of four drugs called PARP-inhibitors that work by shutting down a pathway cancer cells use to reproduce.

The study from Memorial Sloan Kettering Cancer Center in New York randomly treated 300 women with advanced, BRCA-mutated cancer with olaparib or chemotherapy. All the participants had already received two rounds of chemotherapy.

About 60% of patients who received olaparib saw tumors shrink, compared with 29% of patients who received chemotherapy. That meant patients who received olaparib saw cancer advance in seven months, versus four months for only chemotherapy.

Researchers cautioned it is unclear whether olaparib extended life for these patients, and that more research was needed to find out which subset of patients benefit most from olaparib.

Go here to read the rest:
New therapy offers hope against incurable form of breast cancer - The Guardian

Read More...

A New Gene Therapy Could Hold the Key to Curing Allergies and Asthma – Futurism

June 6th, 2017 11:46 pm

In Brief Researchers have successfully used immunotherapy to "turn off" asthma and allergic responses in animals. This work will eventually be used to create one-shot treatments that permanently silence allergies. Erasing Asthma

Scientists from the University of Queensland have used gene therapy to turn off the immune response responsible for asthma. The team believes their technique may also be able to permanently silence severe allergy responses to common allergens such as bee venom, peanuts, and shellfish. Thus far, the research has been successful in animal trials, and if it can be replicated in human trials, it may provide a one-time treatment for asthma and allergy patients.

The technique erases the memory of the cells which cause allergic reactions using genetically modified stem cells that are resistant to allergens. We have now been able wipe the memory of these T-cells in animals with gene therapy, de-sensitizing the immune system so that it tolerates the [allergen] protein, lead researcher Ray Steptoe said in a press release. We take blood stem cells, insert a gene which regulates the allergen protein and we put that into the recipient. Those engineered cells produce new blood cells programmed to express the protein and target specific immune cells, which turn off the allergic response.

According to the Centers for Disease Control (CDC), about 1 in 12 people (25 million) in the U.S.have asthma, and these numbers are increasing annually. As of 2007, the last year for which the CDC has data, asthma cost the U.S. approximately $56 billion in costs for medical bills, lost work and school days, and early deaths. According to the World Health Organization (WHO), 235 million people worldwide have asthma, which is the most common chronic childhood disease, occurring in all countries regardless of level of development.

The researchers findings must now besubjected to further pre-clinical investigation, with the aim of replicating the results in the laboratory using human cells. The longer term goal will be a one-time gene therapy injection that would replace short-term allergy treatments, which vary in their effectiveness. We havent quite got it to the point where its as simple as getting a flu jab so we are working on making it simpler and safer so it could be used across a wide cross-section of affected individuals, Dr. Steptoe said in the press release.

Read more from the original source:
A New Gene Therapy Could Hold the Key to Curing Allergies and Asthma - Futurism

Read More...

Page 990«..1020..989990991992..1,0001,010..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick